Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes
- PMID: 7700004
- DOI: 10.1038/ki.1994.444
Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes
Abstract
There are several ways of experimentally studying the influence of candidate genes on hypertension. The approach proposed here is antisense inhibition with antisense oligodeoxynucleotides (AS-ODNs) constructed to the 5' region of known sequences of angiotensinogen mRNA and angiotensin II type-1 receptor mRNA. The AS-ODNs were applied in vivo and in vitro. In vivo, direct injection of 50 micrograms of AS-ODN into the lateral ventricles of SHR reduced hypertension significantly (P < 0.01). There was no effect of AS-ODN i.c.v. in normotensive WKY rats. The phosphorothiated AS-ODN to the AT1 receptor mRNA also produced a long-lasting decrease in blood pressure in SHR (7 days). After AS-ODN treatment AT1 receptors were reduced in the PVN and anterior third ventricle area and Ang II levels were reduced in the brainstem. The results show the in vivo feasibility of using antisense inhibition of renin-angiotensin mRNA to reduce hypertension.
Similar articles
-
Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.Biosci Rep. 2019 Jan 11;39(1):BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31. Biosci Rep. 2019. PMID: 30530571 Free PMC article. Review.
-
Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.Regul Pept. 1993 Dec 10;49(2):167-74. doi: 10.1016/0167-0115(93)90438-e. Regul Pept. 1993. PMID: 8134617
-
Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.Hypertension. 1998 Jun;31(6):1317-23. doi: 10.1161/01.hyp.31.6.1317. Hypertension. 1998. PMID: 9622148
-
Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats.J Hypertens. 2000 Jun;18(6):725-31. doi: 10.1097/00004872-200018060-00010. J Hypertens. 2000. PMID: 10872557
-
Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid.Am J Cardiol. 1998 Nov 19;82(10A):60S-62S. doi: 10.1016/s0002-9149(98)00680-8. Am J Cardiol. 1998. PMID: 9860363 Review. No abstract available.
Cited by
-
Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.Biosci Rep. 2019 Jan 11;39(1):BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31. Biosci Rep. 2019. PMID: 30530571 Free PMC article. Review.
-
Brain renin angiotensin in disease.J Mol Med (Berl). 2008 Jun;86(6):715-22. doi: 10.1007/s00109-008-0331-5. Epub 2008 Apr 2. J Mol Med (Berl). 2008. PMID: 18385968 Free PMC article. Review.
-
Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense.Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9960-5. doi: 10.1073/pnas.93.18.9960. Proc Natl Acad Sci U S A. 1996. PMID: 8790439 Free PMC article.
-
Gene therapy of hypertensive vascular injury.Curr Hypertens Rep. 2000 Feb;2(1):92-7. doi: 10.1007/s11906-000-0065-4. Curr Hypertens Rep. 2000. PMID: 10981134 Review.
-
Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen.Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3975-80. doi: 10.1073/pnas.96.7.3975. Proc Natl Acad Sci U S A. 1999. PMID: 10097148 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous